Kazia Therapeutics Ltd KZIA
$13.41 $0.27 (1.94%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
KZIA Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Kazia Therapeutics Ltd is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Kazia Therapeutics Ltd. Stock Analysis KZIA
United States Health Care Micro Cap Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company is headquartered in Sydney, New South Wales. The firm operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. The company designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Kazia Therapeutics Ltd (KZIA) Chart
Financial Metrics & Statements of Kazia Therapeutics Ltd (KZIA)
FAQ's for Kazia Therapeutics Ltd (KZIA)
- As of August 2026, Kazia Therapeutics Ltd KZIA is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Kazia Therapeutics Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in Kazia Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Kazia Therapeutics Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Kazia Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Kazia Therapeutics Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Kazia Therapeutics Ltd (KZIA)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
